Why Pacira BioSciences Skyrocketed Today

PCRX surged 44% after Viatris (VTRS) agreed to acquire Pacira BioSciences for $36.50 per share in cash, a deal valuing the company at roughly $1.65 billion. The price carries a 45% premium to PCRX's prior close, so the stock's move landed almost exactly on the offer terms.

The strategic target is Pacira's non-opioid pain management portfolio, led by Exparel and Zilretta. VTRS plans to use those products to strengthen its innovative medicines business. Management expects the transaction to close by the end of 2026.

Interpretation: a 44% pop against a 45% premium suggests the market is pricing a high probability of completion, with only a thin gap between the trading price and the $36.50 offer. That narrow spread, combined with a close date as far out as year-end 2026, means the remaining upside in PCRX is tied to deal timing rather than fundamentals or a competing bid.

For VTRS, the purchase shifts attention to how it funds a $1.65 billion acquisition and how quickly Exparel and Zilretta can contribute to its innovative medicines segment.